Acesis BioMed is a Colorado-based biomedical company focusing on treatment for hypogonadism (low testosterone).
- Low T is also linked to indications such as NAFLD, obesity, and Klinefelter syndrome
- Hypogonadism provides Acesis with a huge market of $3-4 billion. As an underserved indication, Acesis has an opportunity to provide treatment for anywhere between 10% and 40% of the global male population.
- The company’s proprietary “first-in-class” peptide T modulator is expected to provide a safer solution to the existing Testosterone Replacement Therapy (TRT).